[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.124.106. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 8,944
Citations 0
Health Agencies Update
September 27, 2016

Zika Vaccine Enters Clinical Trials

JAMA. 2016;316(12):1249. doi:10.1001/jama.2016.12760

As the first local mosquito-borne transmissions of the Zika virus are being reported in the continental United States, an investigational vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) is entering phase 1 clinical trials.

At least 80 people between the ages of 18 and 35 years will be enrolled in the trial, which will take place at 3 study sites in the United States including the NIH Clinical Center in Bethesda, Maryland. The trial will test vaccine safety and immunogenicity.

First Page Preview View Large
First page PDF preview
First page PDF preview
×